Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENRICH-TAVI: Edoxaban to Prevent Subclinical Valve Leaflet Thrombosis After TAVI in Atrial Fibrillation
jRCTs071180025Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of edoxaban in aortic stenosis (AS) and Atrial fibrillation (AFib), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in maximal leaflet thickness. Started Jan 2020; status: completed.
02
Drugs
edoxaban
03
Conditions
aortic stenosis (AS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on jRCTs071180025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180025.